David E. Nichols

Q: What Schools Are Affiliated With David E. Nichols

David E. Nichols is affiliated with the following schools: University of Cincinnati, Indiana University, Purdue University, University of Iowa, University of North Carolina at Chapel Hill

David E. Nichols's AcademicInfluence.com Rankings

David E. Nichols

Medical

#45

World Rank

#80

Historical Rank

#25

USA Rank

Pharmacology

World Rank

Historical Rank

USA Rank

medical Degrees

David E. Nichols

Chemistry

#206

World Rank

#437

Historical Rank

#111

USA Rank

Organic Chemistry

#300

World Rank

#365

Historical Rank

#79

USA Rank

chemistry Degrees

Download Badge

Medical
Chemistry

David E. Nichols's Degrees

PhD Medicinal Chemistry University of Iowa
Bachelors Pharmacy University of Cincinnati

Why Is David E. Nichols Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David Earl Nichols is an American pharmacologist and medicinal chemist. Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the method that is used to make the optical isomers of hallucinogenic amphetamines. His contributions include the synthesis and reporting of escaline, LSZ, 6-APB, 2C-I-NBOMe and other NBOMe variants , and several others, as well as the coining of the term "entactogen".

(See a Problem?)

David E. Nichols's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Brine shrimp: a convenient general bioassay for active plant constituents. (1982) (4465)
Functional Selectivity and Classical Concepts of Quantitative Pharmacology (2007) (1078)
Serotonin receptors. (2008) (702)
Psychedelics (2016) (654)
Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. (1986) (492)
Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. (1986) (288)
Crystal Structure of an LSD-Bound Human Serotonin Receptor (2017) (273)
Effects of Schedule I drug laws on neuroscience research and treatment innovation (2013) (240)
Serotonergic basis of antipsychotic drug effects in schizophrenia (1998) (212)
An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. (1998) (196)
Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. (1987) (192)
Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists (2006) (189)
Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. (1982) (185)
Brine shrimp: a convenient general bioassay for active plant constituents. (1982) (181)
Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. (1991) (176)
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor (2020) (172)
trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. (1990) (160)
Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. (1986) (158)
The G Protein–Biased κ-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo (2015) (155)
Modification and evaluation of the potato disc assay and antitumor screening of euphorbiaceae seeds. (1982) (147)
Serotonin 5-Hydroxytryptamine2A Receptor-Coupled Phospholipase C and Phospholipase A2 Signaling Pathways Have Different Receptor Reserves (2003) (146)
Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. (1991) (141)
WAY-100635 is a potent dopamine D4 receptor agonist (2006) (141)
Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. (2002) (132)
The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. (1995) (127)
D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. (1991) (120)
A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases (2003) (114)
[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. (1991) (113)
Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis (2005) (109)
Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. (1992) (109)
Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. (1989) (107)
Asymmetric synthesis of psychotomimetic phenylisopropylamines. (1973) (106)
Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. (1996) (105)
Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. (2001) (97)
Psychedelic Drugs in Biomedicine. (2017) (96)
Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. (2000) (95)
Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. (2004) (92)
Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. (1998) (89)
1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. (2006) (88)
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research (2019) (88)
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia (2007) (88)
Structure‐Activity Relationships of MDMA and Related Compounds: A New Class of Psychoactive Drugs? a (1990) (87)
Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. (2002) (85)
A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia (2007) (85)
Reinforcing effects of certain serotonin-releasing amphetamine derivatives (1996) (83)
Absolute configuration and psychotomimetic activity. (1978) (83)
Drug discrimination studies with MDMA and amphetamine (2004) (81)
Nickel boride/hydrazine hydrate reduction of aromatic and aliphatic nitro compounds. Synthesis of 4-(benzyloxy)indole and .alpha.-alkyltryptamines (1986) (80)
Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. (1999) (78)
Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). (1990) (76)
Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphotidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors (1994) (76)
Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. (2005) (75)
Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. (1997) (75)
p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. (1992) (69)
Spare receptors and intrinsic activity: Studies with D1 dopamine receptor agonists (1995) (68)
A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. (1998) (67)
Differential Activation of Adenylate Cyclase and Receptor Internalization by Novel Dopamine D1 Receptor Agonists (2005) (67)
D1 dopamine receptors. (2001) (67)
Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. (1991) (65)
Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. (1993) (65)
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. (1996) (64)
Common receptors for hallucinogens in rat brain: a comparative autoradiographic study using [125I]LSD and [125I]DOI, a new psychotomimetic radioligand (1989) (63)
Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). (2002) (63)
N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues (2014) (61)
High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. (2008) (61)
Parkinson's disease and D1 dopamine receptors. (2001) (60)
LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors (1995) (60)
Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine. (1993) (59)
Serotonin 5‐HT2A receptor activation induces 2‐arachidonoylglycerol release through a phospholipase c‐dependent mechanism (2006) (59)
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. (1994) (58)
8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: A Potent Full Dopamine D1 Agonist Containing a Rigid β-Phenyldopamine Pharmacophore (1996) (57)
Psychostimulant-like effects of p-fluoroamphetamine in the rat. (1995) (56)
3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. (1987) (55)
Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists. (1994) (55)
Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action (2007) (55)
Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. (1991) (54)
(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. (1990) (54)
Chemistry and Structure-Activity Relationships of Psychedelics. (2018) (53)
An animal model of schizophrenia based on chronic LSD administration: Old idea, new results (2011) (53)
Assessment of the Roles of Serines 5.43(239) and 5.46(242) for Binding and Potency of Agonist Ligands at the Human Serotonin 5-HT2A Receptor (2007) (53)
[125I]-2-(2,5-Dimethoxy-4-Iodophenyl) aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex (1990) (52)
Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin (1999) (51)
Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine (1990) (51)
Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats (2002) (51)
Structure–activity relationships of serotonin 5‐HT2A agonists (2012) (50)
Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine (1995) (50)
Structure-activity relationships of MDMA-like substances. (1989) (49)
A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor (2002) (48)
Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia (2014) (48)
Ambient Temperature Effects on 3,4-Methylenedioxymethamphetamine-Induced Thermodysregulation and Pharmacokinetics in Male Monkeys (2007) (46)
Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. (1999) (46)
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). (1991) (46)
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. (2006) (46)
Binding to the serotonin 5-HT2 receptor by the enantiohers of 125I-DOI (1987) (45)
5-HT2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex. (1996) (44)
Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease. (2001) (44)
Dopamine agonist properties of N-alkyl-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines. (1981) (44)
Social Reactivity and D1 Dopamine Receptors: Studies in Mice Selectively Bred for High and Low Levels of Aggression (1994) (44)
Psilocybin: from ancient magic to modern medicine (2020) (42)
Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. (2013) (42)
Structural correlation between apomorphine and LSD: involvement of dopamine as well as serotonin in the actions of hallucinogens. (1976) (41)
Structure-activity relationships of phenethylamine hallucinogens. (1981) (40)
Differential phospholipase C activation by phenylalkylamine serotonin 5‐HT2A receptor agonists (2005) (40)
In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol (2002) (40)
5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. (1993) (40)
“Full” dopamine D1 agonists in human caudate: Biochemical properties and therapeutic implications (1995) (39)
α1-Adrenergic receptors mediate the locomotor response to systemic administration of (±)-3,4-methylenedioxymethamphetamine (MDMA) in rats (2007) (39)
An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA (2002) (38)
Behavioral, biochemical and neurotoxicological actions of the alpha-ethyl homologue of p-chloroamphetamine. (1990) (38)
Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. (1994) (38)
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD). (2018) (37)
2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. (1991) (37)
Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. (1977) (36)
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. (1994) (36)
N,N-dimethyltryptamine and the pineal gland: Separating fact from myth (2018) (35)
Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ). (2017) (35)
Is LSD toxic? (2018) (35)
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B (2004) (34)
Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue (1991) (34)
Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI (2009) (33)
Synthesis and serotonin receptor affinities of a series of enantiomers of alpha-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors. (1988) (33)
Benzofuran bioisosteres of hallucinogenic tryptamines. (1992) (33)
5-iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine (1991) (32)
The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. (2008) (32)
The History of Psychedelics in Psychiatry (2020) (32)
Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine. (1995) (32)
Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists (2005) (32)
Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration (1989) (31)
Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). (2018) (31)
Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands. (1993) (30)
Potential psychotomimetics. 2. Rigid analogs of 2,5-dimethoxy-4-methylphenylisopropylamine (DOM, STP). (1974) (30)
Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG) (2004) (30)
Silica subsurface amine effect on the chemical stability and chromatographic properties of end-capped immobilized artificial membrane surfaces. (1991) (30)
Novel serotonergic agents. (1993) (30)
Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats. (1986) (30)
A demand for clarity regarding a case report on the ingestion of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) in an Ayahuasca preparation. (2006) (29)
Stereoselective Synthesis of trans-2-(Indol-3-yl)cyclopropylamines: Rigid Tryptamine Analogs (1995) (28)
Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists. (1982) (28)
D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. (2006) (28)
WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D4 receptor activation (2009) (27)
Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats (1991) (27)
Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. (1994) (27)
Studies on the mechanism of p-chloroamphetamine neurotoxicity. (1996) (26)
LSD and phenethylamine hallucinogens: new structural analogy and implications for receptor geometry. (1978) (26)
Synthesis and adrenergic blocking effects of 2-(alkylamino)-3,4-dihydroquinazolines. (1980) (26)
Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA). (1996) (26)
Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats (2004) (26)
Legal highs: the dark side of medicinal chemistry (2011) (25)
Effects of psychotomimetics on vascular strips: studies of methoxylated amphetamines and optical isomers of 2,5-dimethoxy-4-methylamphetamine and 2,5-dimethoxy-4-bromoamphetamine. (1974) (25)
Comparative effects of stereoisomers of psychotomimetic phenylisopropylamines. (1973) (25)
Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents (1998) (25)
Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. (1985) (25)
'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. (2008) (25)
Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. (1997) (25)
3,3',5'-Tri-O-methylpiceatannol and 4,3',5'-tri-O-methylpiceatannol: improvements over piceatannol in bioactivity. (1987) (24)
Potential psychotomimetics. Bromomethoxyamphetamines. (1971) (24)
Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. (1995) (24)
Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. (2003) (24)
Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor (2012) (24)
Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA). (1998) (23)
The Development of Novel Dopamine Agonists (1983) (23)
Comparison of cardiovascular, hyperthermic, and toxic effects of para-methoxyamphetamine (PMA) and 3, 4-methylenedioxyamphetamine (MDA). (1975) (23)
Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). (2017) (23)
Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum (2002) (22)
Comparison of solution conformational preferences for the hallucinogens bufotenin and psilocin using 360-MHz proton NMR spectroscopy. (1981) (22)
Studies of the relationship between molecular structure and hallucinogenic activity (1986) (22)
Neurotoxicity of MDMA (ecstasy): beyond metabolism. (2005) (22)
8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. (2004) (22)
Engineered zinc‐binding sites confirm proximity and orientation of transmembrane helices I and III in the human serotonin transporter (2006) (22)
C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. (2006) (22)
Synthesis and SAR exploration of dinapsoline analogues. (2004) (22)
Distinct Recognition of Substrates by the Human and Drosophila Serotonin Transporters (2003) (21)
Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors. (1995) (20)
Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity. (1998) (20)
Comparative Molecular Field Analysis Using Selectivity Fields Reveals Residues in the Third Transmembrane Helix of the Serotonin Transporter Associated with Substrate and Antagonist Recognition (2008) (20)
Formal synthesis of clavicipitic acid based on biosynthetic proposal (1988) (20)
MDMA transiently alters biogenic amines and metabolites in mouse brain and heart (1989) (20)
Role of Serotoninergic Neurons and 5-HT Receptors in the Action of Hallucinogens (2000) (20)
Specific dopamine D-1 and DA1 properties of 4-(mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue. (1987) (20)
Potential psychotomimetics. 2-Amino-1,2,3,4-tetrahydronaphthalene analogs. (1973) (19)
Complex stimulus properties of LSD: a drug discrimination study with α2-adrenoceptor agonists and antagonists (1995) (19)
Effects of S-(+)- and R-(-)-3,4,dimethoxyphenylisopropylamines in the rat. (1972) (19)
Structural variation and (+)-amphetamine-like discriminative stimulus properties (1991) (19)
5-HT2A/2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat (1997) (19)
Evaluation of isomeric 4-(chlorohydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines as dopamine D-1 antagonists. (1987) (18)
D1 Dopamine Receptors of NS20Y Neuroblastoma Cells Are Functionally Similar to Rat Striatal D1 Receptors (1991) (18)
Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (18)
Ligand-Specific Roles for Transmembrane 5 Serine Residues in the Binding and Efficacy of Dopamine D1 Receptor Catechol Agonists (2012) (18)
Sulfur analogs of psychotomimetic amines. (1976) (18)
Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. (1998) (18)
Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum (1995) (18)
Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. (2002) (17)
Comparison of electrospray ionization and atmospheric pressure photoionization liquid chromatography mass spectrometry methods for analysis of ergot alkaloids from endophyte-infected sleepygrass (Achnatherum robustum). (2016) (17)
Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogues. (1977) (17)
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. (1996) (17)
Substituent branching in phenethylamine-type hallucinogens: a comparison of 1-[2,5-dimethoxy-4-(2-butyl)phenyl]-2-aminopropane and 1-[2,5-dimethoxy-4-(2-methylpropyl)phenyl]-2-aminopropane. (1984) (17)
Striatal dopamine D1 receptor suppression impairs reward-associative learning (2017) (17)
Synthesis of high specific activity 125I‐ and 123I‐labelled enantiomers of 2,5‐dimethoxy‐4‐iodophenylisopropylamine (DOI) (1988) (16)
1-Methylpyridinium-4-(4-phenylmethanethiosulfonate) iodide, MTS-MPP+, a novel scanning cysteine accessibility method (SCAM) reagent for monoamine transporter studies. (2007) (16)
One-pot Claisen rearrangement/O-methylation/alkene isomerization in the synthesis of ortho-methoxylated phenylisopropylamines (1996) (16)
Stereoselective LSD-like activity in d-lysergic acid amides of (R)- and (S)-2-aminobutane. (1992) (16)
1 Medicinal Chemistry and Structure-Activity Relationships (2009) (16)
Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors (2009) (16)
Molecular Drug Design and Dopamine Receptors (1997) (16)
A simple procedure for the preparation of indoles (1984) (16)
Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models. (2018) (16)
Resolution and absolute configuration of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, a potent hallucinogen analogue. (1979) (15)
A reported "new synthesis of lysergic acid" yields only the derailment product: methyl 5-methoxy-4,5-dihydroindolo[4,3-f,g]quinoline-9-carboxylate. (2012) (15)
Synthesis and Pharmacological Examination of Benzofuran, Indan, and Tetralin Analogues of 3,4‐(Methylenedioxy)amphetamine. (1994) (15)
Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands. (2003) (15)
Robinlin: a novel bioactive homo-monoterpene from Robinia pseudoacacia L. (Fabaceae). (2001) (15)
Reduction in brain serotonin markers by α-ethyltryptamine (Monase) (1991) (15)
Mapping the Catechol Binding Site in Dopamine D1 Receptors: Synthesis and Evaluation of Two Parallel Series of Bicyclic Dopamine Analogues (2011) (15)
The Heffter Research Institute: Past and Hopeful Future (2014) (14)
Synthesis and evaluation of N,N-di-n-propyltetrahydrobenz[f]indol-7-amine and related congeners as dopaminergic agonists. (1989) (14)
Serotonin-Related Psychedelic Drugs (2009) (14)
Nonneurotoxic Tetralin and Indan Analogues of 3,4‐(Methylenedioxy)amphetamine (MDA). (1990) (14)
Structure--activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice. (1979) (14)
Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP). (1973) (14)
Assessment of the role of α-methylapinine in the neurotoxicity of MDMA (1991) (14)
A new, potent, conformationally restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene. (1982) (14)
Indan Analogs of Fenfluramine and Norfenfluramine Have Reduced Neurotoxic Potential (1998) (14)
Analytical characterization of bioactive N-benzyl-substituted phenethylamines and 5-methoxytryptamines. (2015) (14)
Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. (1995) (14)
Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives (1994) (13)
Serotonin and serotonin receptors in hallucinogen action (2020) (13)
Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues (1989) (13)
trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo(a)phenanthridine: A Highly Potent Selective Dopamine D1 Full Agonist. (1990) (13)
Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues. (2011) (13)
Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. (2002) (13)
2,3-Dihydroxy-9-amino-9,10-dihydrophenanthrene, a rigid congener of dopamine and isoapomorphine. (1978) (13)
A New, Simple Procedure for the Preparation of 8-Methoxy-2-Tetralone (1995) (13)
Effects of para-methoxyamphetamine (PMA) on the cardiovascular system of the dog. (1974) (13)
Stimulation of presynaptic dopamine autoreceptors by 4-(2-di-n-propylaminoethyl) indole (DPAI). (1984) (12)
trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT2 receptor family (2012) (12)
Dopamine D1 receptor agonists as antiparkinson drugs. (1998) (12)
Effect of beta-alkyl substitution on D-1 dopamine agonist activity: absolute configuration of beta-methyldopamine. (1987) (12)
Structural Analysis of the Extracellular Entrance to the Serotonin Transporter Permeation Pathway* (2010) (12)
Parkinson's disease and D 1 dopamine receptors (2001) (11)
Molecular modeling study of tubulosine and other related ipecac alkaloids (1998) (11)
Dopamine Receptor Subtype-Selective Drugs: D1-Like Receptors (2010) (11)
A new view of the structural relationship between LSD and mescaline (1977) (11)
Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane. (1999) (11)
4‐Aryl‐Substituted 2,5‐Dimethoxyphenethylamines: Synthesis and Serotonin 5‐HT2A Receptor Affinities (2009) (11)
Experimental evaluation of the generalized vibrational theory of G protein-coupled receptor activation (2017) (11)
Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogues of hallucinogenic phenethylamines: lack of LSD-like biological activity. (1984) (11)
Cactus alkaloids. XLVII. N alpha-dimethylhistamine, a hypotensive component of Echinocereus triglochidiatus. (1982) (10)
Distinct Molecular Recognition of Psychostimulants by Human and Drosophila Serotonin Transporters (2004) (10)
CHARACTERIZATION OF THREE NEW PSYCHOTOMIMETICS (2002) (10)
An improved synthesis of 6-hydroxy-4-[2-(di-n-propylamino)ethyl]indole (1990) (10)
EFFECTS OF CERTAIN HALLUCINOGENIC AMPHETAMINE ANALOGS ON THE RELEASE OF (3H)-SEROTONIN FROM RAT BRAIN SYNAPTOSOMES (1982) (10)
Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. (1993) (10)
Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. (1999) (10)
Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD (2022) (10)
Steric effects of substituents on phenethylamine hallucinogens. 3,4-(Methylenedioxy)amphetamine analogues alkylated on the dioxole ring. (1979) (9)
LSD and Its Lysergamide Cousins (9)
Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine. (1997) (9)
CACTUS ALKALOIDS. LIII. CORYPHANTHINE AND O-METHYL- CANDICINE, TWO NEW QUATERNARY ALKALOIDS FROM CORYPHANTHA GREENWOODII (1983) (9)
Potential serotonin 5-HT1A and dopamine D4 receptor modulation of the discriminative stimulus effects of amphetamine in rats (2011) (9)
A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. (2001) (9)
A 5-HT2C receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference (2011) (9)
Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease (2012) (9)
Alternative Formal Synthesis of the Potent D1 Dopamine Agonist Dihydroxy-2,3,7,11b-tetrahydro-1H- naphth[1,2,3-de]isoquinoline: Dinapsoline (1999) (8)
Serotonin Release is Responsible for the Locomotor Hyperactivity in Rats Induced by Derivatives of Amphetamine Related to MDMA (1991) (8)
Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand. (2012) (8)
A new approach for the synthesis of (±)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine (dihydrexidine) (1996) (8)
Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists. (2010) (8)
Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients. (1975) (8)
Conformationally Restricted Tetrahydro-1-benzoxepin Analogues of Hallucinogenic Phenethylamines. (1995) (8)
Guanine nucleotide binding proteins and the regulation of cyclic AMP synthesis in NS20Y neuroblastoma cells: role of D1 dopamine and muscarinic receptors (1991) (8)
Dopamine vascular actions of N-substituted derivatives of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN). (1979) (8)
Effects of rigid amphetamine analogs on vascular strips: studies of 2-aminotetrahydronaphthalene and 2-aminoindan derivatives. (1974) (8)
Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance by Griffiths et al. (2006) (8)
A Practical and Cost-Effective Synthesis of 6,7-Dimethoxy-2-tetralone (1999) (8)
Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent (1995) (7)
Effect of a chiral 4-alkyl substituent in hallucinogenic amphetamines. (1995) (7)
SYNTHESIS AND LSD-LIKE DISCRIMINATIVE STIMULUS PROPERTIES IN A SERIES OF N(6)-ALKYL NORLYSERGIC ACID N,N-DIETHYLAMIDE DERIVATIVES (1985) (7)
Synthesis and Pharmacological Examination of 1‐(3‐Methoxy‐4‐methylphenyl)‐2‐aminopropane and 5‐Methoxy‐6‐methyl‐2‐aminoindan: Similarities to 3,4‐(Methylenedioxy)methamphetamine (MDMA). (1991) (7)
Discovery of novel psychoactive drugs: has it ended? (1987) (7)
Isomeric cyclopropyl ring-methylated homologues of trans-2-(2,5-dimethoxy-4-methylphenyl)cyclopropylamine, an hallucinogen analogue. (1982) (7)
A simple organ bath for electrical stimulation and superfusion of rat brain slices. (1986) (7)
Conformational energy differences between side chain alkylated analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane. (1980) (7)
Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. (2012) (7)
Dinapsoline : Characterization of a D 1 Dopamine Receptor Agonist in a Rat Model of Parkinson ’ s Disease (2001) (7)
New victims of current drug laws (2013) (7)
Mescaline analogs: substitutions at the 4-position. (1978) (7)
AN IMPROVED SYNTHESIS OF 1-BENZOYL-4-KETO-1,2,2A,3,4,5-HEXAHYDROBENZ [cd]INDOLE (1977) (7)
Therapeutic and adjunctive applications of an imidazoline anti-inflammatory agent. (1983) (7)
An Efficient Synthesis of the Potent Dopamine D1 Agonist Dinapsoline by Construction and Selective Reduction of 2′-Azadimethoxybenzanthrone (2001) (6)
Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. (2011) (6)
Unreliability of the rat stomach fundus as a predictor of hallucinogenic activity in substituted phenethylamines. (1984) (6)
Lysergamides revisited. (1994) (6)
An economical screen for phenethylamine-type hallucinogens: mouse ear scratching. (1979) (5)
Synthesis and Pharmacological Characterization of a Series of Geometrically Constrained 5-HT 2 A / 2 C Receptor Ligands (5)
Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA. (1991) (5)
Mechanisms and Issues Relating to the Use of D1-like Dopamine Receptor Agonists for Age-related Illnesses: Parkinson’s Disease and Memory and Cognition (2004) (5)
Pharmacologic evaluation of 3,4-dimethoxyphenylpropenes and 3,4-dimethoxyphenylpropanediols. (1972) (5)
AN IMPROVED METHOD FOR THE PREPARATION OF CYCLIC CONJUGATED NITROOLEFINS (1996) (5)
Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release (2005) (5)
C(2)-Methylation abolishes DA1 dopamine agonist activity of 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (6,7-ADTN): steric intolerance by the receptor. (1984) (5)
Tomoxetine and the stereoselectivity of drug action (1987) (5)
Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated (2022) (5)
Cactus alkaloids XXXIII: beta-phenethylamines from the Guatemalan cactus Pilosocereus maxonii. (1977) (4)
The Pharmacodynamic Characterization of an Antisense Oligonucleotide Against Monoamine Oxidase-B (MAO-B) in Rat Brain Striatal Tissue (2001) (4)
(±)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors (1996) (4)
Chemistry and pharmacological evaluation of 1-phenyl-2-propanols and 1-phenyl-2-propanones. (1971) (4)
3,4- Methylenedioxy amphetamine (MDA) Analogues (1989) (4)
Nickel Boride/Hydrazine Hydrate: Reduction of Aromatic and Aliphatic Nitro Compounds. Synthesis of 4‐(Benzyloxy)indole and α‐Alkyltryptamines. (1987) (4)
Emerging Designer Drugs (2014) (4)
Borohydride Reduction of Estrone. Demonstration of Diastereoselectivity in the Undergraduate Organic Chemistry Laboratory (2008) (4)
SYNTHESIS AND ADRENERGIC BLOCKING EFFECTS OF 2-(ALKYLAMINO)-3,4-DIHYDROQUINAZOLINES (1981) (3)
SUBSTITUENT BRANCHING IN PHENETHYLAMINE‐TYPE HALLUCINOGENS: A COMPARISON OF 1‐(2,5‐DIMETHOXY‐4‐(2‐BUTYL)PHENYL)‐2‐AMINOPROPANE AND 1‐(2,5‐DIMETHOXY‐4‐(2‐METHYLPROPYL)PHENYL)‐2‐AMINOPROPANE (1984) (3)
Helix XI contributes to the entrance of the serotonin transporter permeation pathway (2008) (3)
Synthesis and serotonin-like activity of 2-amino-5,8-dimethoxy-6-methyl-1,2-dihydronaphthalene. (1981) (3)
Comparison of the enantiomers of ( ± )-doxanthrine , a high efficacy full dopamine D 1 receptor agonist , and a reversal of enantioselectivity at D 1 versus alpha 2 C adrenergic receptors Running Title : Novel enantioselectivity of doxanthrine (2015) (3)
Drugs in Central Nervous System Disorders (1986) (3)
Homologous Desensitization of the D 1 A Dopamine Receptor : Efficacy in Causing Desensitization Dissociates from Both Receptor Occupancy and Functional Potency 1 (1998) (3)
Effect of α-methyltryptamine on spontaneous activity in mice (1979) (3)
Serotonin Neurotoxicity in Rats After Combined (2001) (3)
A Facile Method for the Preparation of Pure cis‐2,4‐Pentanediol (2004) (3)
A Novel and Efficient Synthesisof Dihydrexidine (2009) (3)
Apomorphine-like effect of an aminotetralin on the linguomandibular reflex of the cat. (1975) (3)
Preliminary evaluation of 4-(2-N,N-dialkylaminoethyl)indoles as potential dopamine agonists (1991) (3)
Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). (1991) (3)
Transgenic Animal (2020) (3)
The use of rigid analogues to probe hallucinogen receptors. (1978) (2)
Native fluorescence and hallucinogenic potency of some amphetamines (2005) (2)
1‐Methyl‐3‐piperidone and 1‐methyl‐3‐pyrrolidone derivatives from a dieckmann reaction (1973) (2)
Further Definition of the D1 Dopamine Receptor Pharmacophore: Synthesis of trans-6,6a,7,8,9,13b-Hexahydro-5H-benzo(d)naphth(2,1-b) azepines as Rigid Analogues of β-Phenyldopamine. (1997) (2)
Effect of alpha-methyltryptamine on spontaneous activity in mice. (1979) (2)
A new potent and selective DA1 (vascular) dopamine receptor agonist (1990) (2)
Stereoselective Synthesis of trans‐2‐(Indol‐3‐yl)cyclopropylamines: Rigid Tryptamine Analogues. (1995) (2)
A NEW, POTENT, CONFORMATIONALLY-RESTRICTED ANALOG OF AMPHETAMINE: 2-AMINO-1,2-DIHYDRONAPHTHALENE (1982) (1)
Formal Synthesis of Clavicipitic Acid Based on a Biosynthetic Proposal. (1989) (1)
Synthesis und Evaluation of 2,3-Dihydrobenzofuran Analogues of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane: Drug Discrimination Studies in Rats. (1986) (1)
Highly Selective Neurotoxins. Basic and Clinical Applications Edited by R. M. Kostrzewa. Humana Press, Towota, NJ. 1998. xii + 404 pp. 16 × 23.5 cm. ISBN 0-89603-465-8. $125.00. (1998) (1)
The consequences of receptor reserve on agonist-directed trafficking at the serotonin2A receptor (2001) (1)
An Efficient Synthesis of the Potent Dopamine D1 Agonist Dinapsoline (IX) by Construction and Selective Reduction of 2′-Azadimethoxybenzanthrone. (2001) (1)
SYNTHESIS OF 2-(ALKYLAMINO)-5,6- AND -6,7-DIHYDROXY-3,4-DIHYDROQUINAZOLINES AND EVALUATION AS POTENTIAL DOPAMINE AGONISTS (1982) (1)
Author’s reply (2018) (1)
D1 versus D2 dopamine receptor selectivity is determined by intramolecular hydrogen bonding patterns in catechol‐containing novel dopamine analogues (2008) (1)
Signaling Snapshots of 5-HT 2BR Activated by the Prototypical Psychedelic LSD (2022) (1)
Addressing the need for rigor in the rebirth of hallucinogen research (2017) (1)
LIPOPHILICITY AND SEROTONIN AGONIST ACTIVITY IN A SERIES OF 4-SUBSTITUTED MESCALINE ANALOGS (1977) (1)
In vitro and in vivo evaluation of cis-methyl-phencyclidine (CIS-MPCP) as a potential antagonist of phencyclidine (PCP). (1983) (1)
A New, Simple Procedure for the Preparation of 8‐Methoxy‐2‐tetralone. (1995) (1)
A Novel and Efficient Synthesis of Dihydrexidine A New Synthesis of Dihydrexidine (2009) (1)
One‐Pot Claisen Rearrangement/O‐Methylation/Alkene Isomerization in the Synthesis of ortho‐Methoxylated Phenylisopropylamines. (1997) (1)
An unusual formation of a novel spiroisoquinolone ring (1995) (1)
The Medicinal Chemistry of Phenethylamine Psychedelics (1)
Crystal structure of the LSD-bound 5-HT2B receptor (2017) (1)
LSD and the Serotonin System's Effects on Human Consciousness (2011) (1)
Lsd: cultural revolution and medical advances (2006) (1)
Effects of steric interactions on models of charge-transfer complexes: A preliminary report (2009) (1)
Designer Drugs Directory By Karel Valter and Philippe Arrizabalaga. Edited by Jean-Claude Landry. Elsevier Science, Lausanne, Switzerland. 1998. 212 pp. 17 x 25 cm. ISBN 0-444-20525-X. $154.00. (1999) (1)
A Chemogenetic Platform for Spatio-temporal Control of β-arrestin Translocation and Signaling at G protein-Coupled Receptors (2018) (1)
ISOMERIC CYCLOPROPYL RING-METHYLATED HOMOLOGS OF TRANS-2-(2,5-DIMETHOXY-4-METHYLPHENYL)CYCLOPROPYLAMINE, AN HALLUCINOGEN ANALOG (1982) (1)
Excitatory Amino Acids and Their Antagonists (2015) (1)
Stereoselective effects of MDMA on inhibition of monoamine uptake (1986) (1)
Alternative Formal Synthesis of the Potent D1 Dopamine Agonist Dihydroxy‐2,3,7,11b‐tetrahydro‐1H‐naphth[1,2,3‐de]isoquinoline: Dinapsoline. (1999) (0)
A New Approach for the Synthesis of (.+-.)-trans-10,11-Dihydroxy-5,6, 6a,7,8,12b-hexahydrobenzo(a)phenanthridine (Dihydrexidine). (1996) (0)
Specific Dopamine D-1 and DA1 Properties of 4-(Mono- and -dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and Its Tetrahydrothieno(2,3-c)pyridine Analogue. (1988) (0)
1-( 2 , 5-Dimethoxy-4-( trifluoromethy 1 ) phenyl )-2-aminopropane : A Potent Serotonin ~-H T ~ A / ~ c Agonist (2001) (0)
2365 – A COMPARATIVE STUDY OF N-N-DISUBSTITUTED ANALOGS OF DOPAMINE AND 2-AMINO-6,7-DIHYDR0XY-TETRALIN (1978) (0)
1-METHYL-3-PIPERIDONE AND 1-METHYL-3-PYRROLIDONE DERIVATIVES FROM A DIECKMANN REACTION (1973) (0)
Striatal dopamine D 1 receptor suppression impairs reward-associative learning Running title : Striatal D 1 receptors in reward learning (2017) (0)
EJP 53172 5H T 2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits (2002) (0)
SA113. Dopamine D1 Receptor Activation Improves Reward-Associative Learning in a Mouse Probabilistic Learning Task (2017) (0)
AN IMPROVED SYNTHESIS OF 1-BENZOYL-4-OXO-1,2,2A,3,4,5-HEXAHYDROBENZ(CD)INDOLE (1978) (0)
C(2)-METHYLATION ABOLISHES DA1 DOPAMINE AGONIST ACTIVITY OF 2-AMINO-6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE (6,7-ADTN): STERIC INTOLERANCE BY THE RECEPTOR (1985) (0)
icrodialysis studies on 3 , 4 methylenedioxyamphetamine a related analogues (2002) (0)
An Improved Synthesis of 6-Hydroxy-4-(2-(di-n-propylamino)ethyl)indole. (1990) (0)
Dihydrobenzofuran Analogues of Hallucinogens. Part 4. Mescaline Derivatives. (1998) (0)
Comparison of the behavioral effects of para-chloroamphetamine, chlordimeform, quipazine, and intraventricular serotonin in the rat. (1978) (0)
Conformational energy calculations of some amphetamine analogs using a new solvation model (2009) (0)
Selective sparing of neuronal subpopulations in the striatum in glutaric aciduria type 1 (2006) (0)
Effects of the N343A mutation in TM6 of the human serotonin 5‐HT2A Receptor (2006) (0)
Proposed Consensus Statement on Defining Psychedelic Drugs (2022) (0)
Allylbenzene analogs of delta9-tetrahydrocannabinol as tumor growth inhibitors. (1977) (0)
(trifluoromethy1)phenyl) -2-aminopropane: A Potent Serotonin ~-HT~A/~c Agonist (1994) (0)
Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease (2012) (0)
A Facile Method for the Preparation of Pure cis‐2,4‐Pentanediol. (2004) (0)
Using Comparative Molecular Field Analysis (CoMFA) selectivity fields to determine effects of point mutations on ligand recognition at serotonin transporters (2007) (0)
8,9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph(1,2,3-de)isoquinoline: A Potent Full Dopamine D1 Agonist Containing a Rigid β- Phenyldopamine Pharmacophore. (1996) (0)
SULFUR ANALOGS OF PSYCHOTOMIMETIC AMINES (1977) (0)
Erratum: Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase (Journal of Pharcology and Experimental Therapeutics (2002) 301 (1166-1179)) (2002) (0)
Preface to the special issue “Psychedelics and Neurochemistry” (2022) (0)
Synthesis of Essential Drugs By Ruben Vardanyan and Victor Hruby. Elsevier, Amsterdam, The Netherlands. 2006. xvi + 617 pp. 17 × 24.5 cm. ISBN 10 0-444-52166-6. $240.00. (2006) (0)
Hallucinogens. (1964) (0)
Psilocybin: from ancient magic to modern medicine (2020) (0)
STERIC EFFECTS OF SUBSTITUENTS ON PHENETHYLAMINE HALLUCINOGENS. 3,4-(METHYLENEDIOXY)AMPHETAMINE ANALOGS ALKYLATED ON THE DIOXOLE RING (1980) (0)
THE ROLE OF THREONINE3.37 [T3.37] IN D1‐LIKE DOPAMINE RECEPTOR ACTIVATION (2006) (0)
A Practical and Cost‐Effective Synthesis of 6,7‐Dimethoxy‐2‐tetralone. (2000) (0)
SYNTHESIS AND EVALUATION OF SUBSTITUTED 2-PHENYLCYCLOBUTYLAMINES AS ANALOGS OF HALLUCINOGENIC PHENETHYLAMINES: LACK OF LSD-LIKE BIOLOGICAL ACTIVITY (1985) (0)
Hypothetical Models Of Dopamine D-1 Receptor (1990) (0)
ASYMMETRIC SYNTHESIS OF PSYCHOTOMIMETIC PHENYLISOPROPYLAMINES (1973) (0)
Psychedelic Drugs (2021) (0)
SYNTHESIS AND SEROTONIN-LIKE ACTIVITY OF 2-AMINO-5,8-DIMETHOXY-6-METHYL-1,2-DIHYDRONAPHTHALENE (1981) (0)
An Unusual Formation of a Novel Spiroisoquinolone Ring. (1995) (0)
2,3-DIHYDROXY-9-AMINO-9,10-DIHYDROPHENANTHRENE, A RIGID CONGENER OF DOPAMINE AND ISOAPOMORPHINE (1978) (0)
Identification of residues lining the entrance of the human serotonin transporter substrate permeation pathway using homology modeling (2008) (0)
Ligand‐specific roles for transmembrane 5 serine residues in D1 dopamine receptor binding and activation (2010) (0)
Potential Psychotomimetics . 2 . l Rigid Analogs of 2 , 5-Dimet hoxy-4-met hy lpheny 1 isoDropy lamine ( D OM , STP ) (2001) (0)
Allylbenzene analogs of Δ9-tetrahydrocannabinol as tumor growth inhibitors (1977) (0)
Translocation of the 5‐Alkoxy Substituent of 2,5‐Dialkoxyarylalkylamines to the 6‐Position: Effects on 5‐HT2A/2C Receptor Affinity. (2002) (0)
Synthesis and Biological Evaluation of a Series of Substituted Benzo(a) phenanthridines as Agonists at D1 and D2 Dopamine Receptors. (1995) (0)
Highs and lows (2010) (0)
C-ring expanded analogs of doxanthrine:conformation plays a critical role (2011) (0)
STRUCTURE-ACTIVITY RELATIONSHIPS OF N-SUBSTITUTED DOPAMINE AND 2-AMINO-6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE ANALOGS: BEHAVIORAL EFFECTS IN LESIONED AND RESERPINIZED MICE (1980) (0)
Synthesis and Pharmacological Examination of Benzofuran , Indan , and Tetralin Analogues of 3 , 4-( Methy 1 enedioxy ) amphetamine (2002) (0)
Methoxyphenethylamine-ergoline hybrids Novel muscarinic ligands (1995) (0)
RESOLUTION AND ABSOLUTE CONFIGURATION OF TRANS-2-(2,5-DIMETHOXY-4-METHYLPHENYL)CYCLOPROPYLAMINE, A POTENT HALLUCINOGEN ANALOG (1979) (0)
Asymmetric Synthesis of Psycho tomimetic Phenylisopropylamines ' (2009) (0)
Behavioral techniques in neuroreceptor research. (1983) (0)
Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (0)
Synthesis of high specific activity radiohalogenated amphetamine analogues for studies of the serotonin 5‐HT2 receptor (1989) (0)
DOPAMINE AGONIST PROPERTIES OF N-ALKYL-4-(3,4-DIHYDROXYPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINES (1982) (0)
Signaling snapshots of 5-HT 2B serotonin receptor activated by the prototypical psychedelic LSD (2022) (0)
Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (0)
POTENTIAL PSYCHOTOMIMETICS, 2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE ANALOGS (1973) (0)
STRUCTURE-ACTIVITY RELATIONSHIPS OF PHENETHYLAMINE HALLUCINOGENS (1982) (0)
Phe340 with super-potent N-benzyl phenethylamine agonists (2006) (0)
Serotonin 5‐HT2A Receptor‐Coupled 2‐Arachidonoylglycerol (2‐AG) Release (2006) (0)
Ligand and G-protein selectivity in the κ-opioid receptor. (2023) (0)
COMPARISON OF SOLUTION CONFORMATIONAL PREFERENCES FOR THE HALLUCINOGENS BUFOTENIN AND PSILOCIN USING 360-MHZ PROTON NMR SPECTROSCOPY (1981) (0)
Stereochemical and NMR Reassignment of 6-Norlysergic Acid Diethylamide and 6-Nor-6-allyllysergic Acid Diethylamide. (1996) (0)
An Improved Method for the Preparation of Cyclic Conjugated Nitroolefins. (1996) (0)
Correction to: Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) (2018) (0)
Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor (2012) (0)
The Chemistry of Mind-Altering Drugs. History, Pharmacology, and Cultural Context By Daniel M. Perrine. American Chemical Society, Washington, D.C. 1996. x + 480 pp. 17.5 × 25 cm. ISBN 0-8412-3253-9. $39.95. (1997) (0)
Po ten tial Psychotomimetics . 2-Amino-1 , 2 , 3 , 4-te trahy dro naph thalene Analogs ? (2002) (0)
Remove barriers to clinical research for schedule 1 drugs with therapeutic potential (2023) (0)
New fused isoquinolines as receptor ligands dopamine. (1996) (0)
CONFORMATIONAL ENERGY DIFFERENCES BETWEEN SIDE CHAIN ALKYLATED ANALOGS OF THE HALLUCINOGEN 1-(2,5-DIMETHOXY-4-METHYLPHENYL)-2-AMINOPROPANE (1980) (0)
Synthesis and Evaluation of N,N‐Di(n‐propyl)tetrahydrobenz(f)indol‐7‐amine and Related Congeners as Dopaminergic Agonists. (1990) (0)
POTENTIAL PSYCHOTOMIMETICS PART 2, RIGID ANALOGS OF 2,5-DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM,STP) (1974) (0)
Indan Analogues of 3 , 4-( Met hy 1 enedioxy ) amphetamine (2001) (0)
Preliminary Evaluation of 4-(2-N,N-Dialkylaminoethyl)indoles as Potential Dopamine Agonists. (1991) (0)
Reduction of aspirin-induced ulcers by a new imidazoline anti-inflammatory agent (1981) (0)
Synthesis and Pharmacological Examination of 1-( 3-Methoxy-l-methylphenyl )-2-aminopropane and 5-Methoxy-6-methyl-2-aminoindan : Similarities to 3 , 4-( Met hy 1 enedioxy ) met hamphetamine ( MDMA ) (0)

This paper list is powered by the following services:

Other Resources About David E. Nichols

en.wikipedia.org

What Schools Are Affiliated With David E. Nichols?

David E. Nichols is affiliated with the following schools:

David E. Nichols's Academic­Influence.com Rankings

David E. Nichols's Degrees

Why Is David E. Nichols Influential?

David E. Nichols's Published Works

Published Works

Other Resources About David E. Nichols

What Schools Are Affiliated With David E. Nichols?

David E. Nichols's AcademicInfluence.com Rankings